Personalised antiplatelet therapy for patients with narrowing/blocked blood supply to their legs

Not Applicable

• Conditions: Resistance to antiplatelet therapy in patients with peripheral arterial disease; Circulatory System

• Registration Number: ISRCTN10495682
• Lead Sponsor: niversity of Leicester

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-11-01
• Last Update Posted: 13 November 2023
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Aged 18 years old and over
2. Severely symptomatic aorto-iliac and infra-inguinal peripheral arterial disease
3. Ability to provide written informed consent
4. Patients on antiplatelet therapy

Exclusion Criteria

1. Aged 17 years old and under
2. Unable or unwilling to provide written informed consent
3. Acute limb ischaemia of the lower limb
4. Aneurysmal disease of the arteries of the lower limb
5. Severe diabetic foot sepsis
6. A known history of clotting disorders
7. Inherited bleeding disorders

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Feasibility of using the VerifyNow PRU and Aspirin assays measured using the obtained estimates of the prevalence of resistance to antiplatelet therapy (aspirin & clopidogrel) in patients with symptomatic peripheral arterial disease at 18 months

Secondary Outcome Measures

Name	Time	Method
To examine whether resistance to antiplatelet therapy is associated with major adverse cardiac or limb events during the follow-up interval of one year measured using the risk ratios in the resistant and non-resistant groups of cumulative incidence of major adverse cardiac/limb events assessed through interrogation of electronic medical records and phone calls with participants at both 6 months and one year follow up